期刊文献+

叶酸修饰羧甲基壳聚糖纳米药物载体的制备及表征 被引量:3

Preparation and characterization of folic acid modified carboxymethyl chitosan nanoparticles for drug delivery
原文传递
导出
摘要 利用金属离子的模板作用,以CaCl_2为交联剂,制备载天然抗癌药物齐墩果酸(OA)的叶酸-O-羧甲基壳聚糖(FA-O-CS)纳米粒子。采用核磁共振氢谱(~1HNMR)、红外光谱仪(FT-IR)和透射电子显微镜(TEM)检测结合物的结构,并对纳米粒子的形貌与大小进行表征。~1HNMR和FT-IR测试结果表明FA与O-CS成功联结。TEM观测到OA/FA-O-CS纳米粒子为球状,粒径均一,约为300nm。 The folic acid-O-carboxymethyl chitosan(FA-O-CS)nanoparticles containing the natural anticancer drug oleanolic acid(OA)were prepared by the template action of metal ions and CaCl2 as a crosslinking agent.The structure of the conjugate was detected by nuclear magnetic resonance spectroscopy(1HNMR),infrared spectroscopy(FT-IR),and transmission electron microscopy(TEM),and the morphology and size of the nanoparticles were characterized.The results of 1HNMR and FT-IR test confirmed that FA and O-CS were successfully connected.TEM observation showed that the OA/FA-O-CS nanoparticles were spherical and uniform in particle size,about 300 nm.
作者 崔翔瑞 苏崟 王英飒 刘六军 CUI Xiang-rui;SU Yin;WANG Ying-sa;LIU Liu-jun(Materials Science and Technology,Beijing Forestry University,Beijing 100083,China)
出处 《精细与专用化学品》 CAS 2019年第3期30-32,共3页 Fine and Specialty Chemicals
基金 北京林业大学2018年大学生科技创新创业训练计划项目(X201810022109)
关键词 天然抗癌药物 叶酸活性酯 纳米药物载体 Ca离子交联法 oleanolic acid folic acid active ester nano drug carrier Ca ion crosslinking
  • 相关文献

参考文献7

二级参考文献224

  • 1张鑫,李鑫钢,姜斌.四氧化三铁纳米粒子合成及表征[J].化学工业与工程,2006,23(1):45-48. 被引量:46
  • 2Peer D, Karp J M, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol, 2007, 2:751-760.
  • 3Davis M E, Chert Z, Shin D M. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discov, 2008, 7: 771-782.
  • 4Deng C, Jiang Y, Cheng R, et al. Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: Promises, pro- gress and prospects. Nano Today, 2012, 7:467-480.
  • 5Torchilin V P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov, 2014, 13:813-827.
  • 6Egusquiagnirre P S, Igartua M, Hernandez R M, et al. Nanoparticle delivery systems for cancer therapy: Advances in clinical and pre- clinical research. Clin Transl Oncol, 2012, 14:83-93.
  • 7Kim T Y, Kim D W, Chung J Y, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric mi- celle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res, 2004, 10:3708-3716.
  • 8Matsumura Y, Hamaguchi T, Ura T, et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxo- rubicin. Br J Cancer, 2004, 91:1775-1781.
  • 9Kato K, Chin K, Yoshikawa T, et al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest New Drugs, 2012, 30:1621-1627.
  • 10Hamaguchi T, Doi T, Eguchi-Nakajima T, et al. Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult pa- tients with solid tumors. Clin Cancer Res, 2010, 16:5058-5066.

共引文献30

同被引文献41

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部